Medicolegal considerations with intravenous tissue plasminogen activator in stroke: A systematic review

Stroke Research and Treatment

Volumn , Issue , 2013, Pages

  Bhatt, Archit ^a   Safdar, Adnan ^a   Chaudhari, Dhara ^a   Clark, Diane ^a   Pollak, Amber ^a   Majid, Arshad ^a   Kassab, Mounzer ^a  

^a MS Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

BRAIN ISCHEMIA; DIAGNOSTIC ERROR; DRUG TREATMENT FAILURE; EXPERT WITNESS; FIBRINOLYTIC THERAPY; HUMAN; INFORMED CONSENT; LAW SUIT; MALPRACTICE; MEDICAL DOCUMENTATION; MEDICOLEGAL ASPECT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84884833502     PISSN: None     EISSN: 20420056     Source Type: Journal    
DOI: 10.1155/2013/562564     Document Type: Review

References (18)

1. Marler J. R., Tissue plasminogen activator for acute ischemic stroke. The New England Journal of Medicine 1995 333 24 1581 1587 2-s2.0-0028783948 10.1056/NEJM199512143332401
2. Fieschi C., Hacke W., Kaste M., Toni D., Lesaffre E., Thrombolytic therapy for acute ischaemic stroke. ECASS Study Group. Lancet 1997 350 9089 1476 1477 2-s2.0-0031573136
3. Clark W. M., Wissman S., Albers G. W., Jhamandas J. H., Madden K. P., Hamilton S., Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset the ATLANTIS study: a randomized controlled trial. Journal of the American Medical Association 1999 282 21 2019 2026 2-s2.0-0033485522 10.1001/jama.282.21.2019
4. Hacke W., Kaste M., Bluhmki E., Brozman M., Dávalos A., Guidetti D., Larrue V., Lees K. R., Medeghri Z., Machnig T., Schneider D., Von Kummer R., Wahlgren N., Toni D., Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. The New England Journal of Medicine 2008 359 13 1317 1329 2-s2.0-52649165720 10.1056/NEJMoa0804656
5. Adams H. P. Jr., Brott T. G., Furlan A. J., Gomez C. R., Grotta J., Helgason C. M., Kwiatkowski T., Lyden P. D., Marler J. R., Torner J., Feinberg W., Mayberg M., Thies W., Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1996 94 5 1167 1174 2-s2.0-0011751506 (Pubitemid 26292882)
6. Position statement of the american academy of emergency medicine on the use of intravenous thrombolytic therapy in the treatment of stroke. http://www.aaem.org/em-resources/position-statements/2002/thrombolytic-therapy
7. Brennan T. A., Sox C. M., Burstin H. R., Relation between negligent adverse events and the outcomes of medical-malpractice litigation. The New England Journal of Medicine 1996 335 26 1963 1967 2-s2.0-0030454632
8. Studdert D. M., Mello M. M., Gawande A. A., Gandhi T. K., Kachalia A., Yoon C., Puopolo A. L., Brennan T. A., Claims, errors, and compensation payments in medical malpractice litigation. The New England Journal of Medicine 2006 354 19 2024 2033 2-s2.0-33646483918
9. Piaa Risk Management Review 2009 Neurology
10. Weintraub M. I., Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. Stroke 2006 37 7 1917 1922 2-s2.0-33745964452 10.1161/01.STR.0000226651.04862.da (Pubitemid 44297752)
11. Liang B. A., Zivin J. A., Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke. Annals of Emergency Medicine 2008 52 2 160 164 2-s2.0-48949117567 10.1016/j.annemergmed.2007.12.017
12. Katzan I. L., Sila C. A., Furlan A. J., Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey. Stroke 2001 32 4 861 864 2-s2.0-0035067986 (Pubitemid 32285149)
13. Katzan I. L., Furlan A. J., Lloyd L. E., Frank J. I., Harper D. L., Hinchey J. A., Hammel J. P., Qu A., Sila C. A., Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. Journal of the American Medical Association 2000 283 9 1151 1158 2-s2.0-0034161611 (Pubitemid 30126603)
14. Reeves M. J., Arora S., Broderick J. P., Frankel M., Heinrich J. P., Hickenbottom S., Karp H., LaBresh K. A., Malarcher A., Mensah G., Moomaw C. J., Schwamm L., Weiss P., Acute stroke care in the us: results from 4 pilot prototypes of the paul coverdell national acute stroke registry. Stroke 2005 36 1232 1240 (Pubitemid 40798745)
15. Brown D. L., Barsan W. G., Lisabeth L. D., Gallery M. E., Morgenstern L. B., Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Annals of Emergency Medicine 2005 46 1 56 60 2-s2.0-21444458290 10.1016/j.annemergmed.2004.12.025 (Pubitemid 40916897)
16. Kleindorfer D., Hill M. D., Woo D., Tomsick T., Pancioli A., Kissela B., Demchuk A. M., Losiewicz D., Jauch E., Schneider A., Ringer A., Kanter D., Broderick J. P., A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke. Stroke 2005 36 3 682 687 2-s2.0-20044382047 10.1161/01.STR.0000155742.46437.65 (Pubitemid 40344180)
17. Edwards L. L., Using tPA for acute stroke in a rural setting. Neurology 2007 68 4 292 294 2-s2.0-33846455399 10.1212/01.wnl.0000253190.40728.0c (Pubitemid 46148342)
18. Pervez M. A., Silva G., Masrur S., Betensky R. A., Furie K. L., Hidalgo R., Lima F., Rosenthal E. S., Rost N., Viswanathan A., Schwamm L. H., Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe. Stroke 2010 41 1 e18 e24 2-s2.0-74049140342 10.1161/STROKEAHA.109.560169